US health agency to negotiate prices for GLP-1 weight-loss drugs
I'm PortAI, I can summarize articles.
Dec 23 (Reuters) - The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug prices with manufacturers of GLP-1 medications, in an attempt to expand access to the weight-loss treatments.Under the initiative, CMS would expand the coverage efforts, with a Medicaid pilot program beginning in May 2026 and a Medicare pilot in January 2027.The programs would cover Novo Nordisk’s (NOVOb.CO) , Wegovy and Ozempic, and Eli Lilly’sZepbound and Mounjaro for weight loss.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments